Roivant Sciences (NASDAQ:ROIV) Reaches New 12-Month High - Should You Buy?

Key Points

• Roivant Sciences reached a new 52-week high, trading as high as $41.62 and last changing hands at $39.03, up 14.1% from its prior close.
• Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating and recent price targets ranging from $41 to $46. However, the consensus target of $35.14 is below the current share price.
• The company remains unprofitable, reporting a quarterly loss of $0.26 per share and $1.44 million in revenue, below expectations. Insiders sold more than 3 million shares worth approximately $107.3 million over the past 90 days.

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) hit a new 52-week high on Tuesday . The company traded as high as $41.62 and last traded at $39.0310, with a volume of 710937 shares trading hands. The stock had previously closed at $34.93.

Analysts Set New Price Targets

ROIV has been the subject of a number of research reports. Piper Sandler restated an "overweight" rating on shares of Roivant Sciences in a report on Thursday, May 21st. HC Wainwright restated a "buy" rating and issued a $41.00 price target on shares of Roivant Sciences in a research note on Friday, August 28th. Citigroup increased their price objective on Roivant Sciences from $42.00 to $46.00 and gave the company a "buy" rating in a research note on Monday, August 10th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Roivant Sciences in a report on Tuesday, August 25th. Finally, Guggenheim increased their price target on Roivant Sciences from $36.00 to $42.00 and gave the company a "buy" rating in a research report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Roivant Sciences presently has a consensus rating of "Moderate Buy" and a consensus price target of $35.14.

Roivant Sciences Trading Up 14.1%

The business's fifty day moving average price is $35.30 and its 200 day moving average price is $31.26. The firm has a market capitalization of $28.79 billion, a price-to-earnings ratio of -75.20 and a beta of 1.12.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last issued its quarterly earnings results on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.04. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%.The firm had revenue of $1.44 million during the quarter, compared to the consensus estimate of $2.06 million. As a group, sell-side analysts forecast that Roivant Sciences Ltd. will post -2 earnings per share for the current fiscal year.

Insider Transactions at Roivant Sciences

In other news, insider Mayukh Sukhatme sold 284,707 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $36.25, for a total value of $10,320,628.75. Following the sale, the insider directly owned 18,630,739 shares in the company, valued at $675,364,288.75. This represents a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Daniel Gold sold 800,000 shares of the company's stock in a transaction on Monday, June 29th. The shares were sold at an average price of $34.55, for a total value of $27,640,000.00. Following the completion of the sale, the director owned 13,701,546 shares in the company, valued at $473,388,414.30. This represents a 5.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 3,055,913 shares of company stock valued at $107,261,258 in the last 90 days. 8.80% of the stock is currently owned by insiders.

Institutional Trading of Roivant Sciences

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Morgan Stanley boosted its position in Roivant Sciences by 31.7% in the 4th quarter. Morgan Stanley now owns 58,359,553 shares of the company's stock valued at $1,266,402,000 after buying an additional 14,036,696 shares during the last quarter. Rubric Capital Management LP raised its holdings in shares of Roivant Sciences by 14.7% during the second quarter. Rubric Capital Management LP now owns 20,370,336 shares of the company's stock worth $229,574,000 after purchasing an additional 2,603,260 shares during the period. State Street Corp grew its position in shares of Roivant Sciences by 4.8% during the 2nd quarter. State Street Corp now owns 19,773,480 shares of the company's stock valued at $222,847,000 after buying an additional 911,827 shares during the last quarter. California State Teachers Retirement System lifted its holdings in Roivant Sciences by 4,212.2% in the second quarter. California State Teachers Retirement System now owns 19,001,068 shares of the company's stock worth $672,448,000 after acquiring an additional 18,560,434 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in Roivant Sciences by 365.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 10,982,633 shares of the company's stock valued at $238,323,000 after acquiring an additional 8,621,567 shares during the period. Institutional investors and hedge funds own 64.76% of the company's stock.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.